William Blair analyst Matt Phipps has maintained their bullish stance on DVAX stock, giving a Buy rating yesterday.
Matt Phipps has given his Buy rating due to a combination of factors including Dynavax’s strategic positioning and growth potential. The company’s management has expressed confidence in reaching the upper half of their financial guidance, driven by positive trends in the adult hepatitis B vaccine market. Additionally, Dynavax’s long-term growth strategy, which involves disciplined capital allocation and the introduction of two new vaccine programs, further supports this optimistic outlook.
Despite a slight miss in first-quarter Heplisav sales compared to estimates, the company’s market share and revenue growth remain strong. Year-over-year market share gains and a 36% revenue increase are particularly encouraging. Management’s focus on maintaining and expanding market share in key segments is expected to bolster investor confidence and support the company’s peak-year estimates, reinforcing the Buy rating.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $25.00 price target.